Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Advancing Corneal Innervation Research Through Innovative Models
Published on: December 8, 2023
Targeting corneal inflammation by gene therapy: Emerging strategies for keratitis
Josune Torrecilla1, Ana Del Pozo-Rodríguez1, Mónica Vicente-Pascual1
1Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de investigación Lascaray ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, Vitoria-Gasteiz, Spain.
Abstract:
Inflammation is the underlying process of several diseases within the eye, specifically in the cornea. Current treatment options for corneal inflammation or keratitis, and related neovascularization, are restricted by limited efficacy, adverse effects, and short duration of action. Gene therapy has shown great potential for the treatment of diseases affecting the ocular surface, and major efforts are being targeted to inflammatory mediators and neovascularization, in order to develop potential treatments for corneal inflammation. Gene therapy to treat ocular disorders is still starting, and current therapies are primarily experimental, with most human clinical trials still in research state, although some of them have already shown encouraging results. In this review, we focus on the progress and challenges of gene therapy to treat corneal inflammation. After introducing the inflammation process, we present the main nucleic acid delivery systems, including viral and non-viral vectors, and the most studied strategies to address the therapy: control of neovascularization and regulation of pro- and anti-inflammatory cytokines.
Insights
Gene therapy offers a promising approach for treating corneal inflammation (keratitis) and neovascularization, addressing limitations of current treatments. Research is advancing, focusing on delivery systems and cytokine regulation for ocular surface diseases.
Area of Science:
- Ophthalmology
- Molecular Biology
- Gene Therapy
Background:
- Corneal inflammation (keratitis) and neovascularization are significant ocular surface diseases.
- Current treatments for keratitis are limited by efficacy, side effects, and short action duration.
Purpose of the Study:
- To review the progress and challenges of gene therapy for corneal inflammation.
- To explore gene therapy's potential for treating ocular surface inflammatory conditions.
Main Methods:
- Discussion of inflammation processes in the cornea.
- Overview of viral and non-viral nucleic acid delivery systems.
- Analysis of therapeutic strategies targeting neovascularization and cytokine regulation.
Main Results:
- Gene therapy shows potential for treating corneal inflammation and neovascularization.
- Experimental gene therapies for ocular disorders are emerging with encouraging clinical trial results.
Conclusions:
- Gene therapy represents a developing frontier for managing corneal inflammation.
- Further research into delivery systems and molecular targets is crucial for clinical translation.
More Related Videos
04:48Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
Published on: November 22, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inflammation
Emerging Adulthood
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response